Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Beauty Health (SKIN) EPS (Weighted Average and Diluted) (2020 - 2025)

Beauty Health (SKIN) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.05 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed 0.0% to -$0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.19 through Dec 2025, up 52.5% year-over-year, with the annual reading at -$0.16 for FY2025, 55.56% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.05 at Beauty Health, up from -$0.09 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.39 in Q4 2021, with the low at -$1.63 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.23, with a median of -$0.08 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 965558.89% in 2021, then tumbled 1766.67% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.39 in 2021, then tumbled by 102.56% to -$0.01 in 2022, then tumbled by 700.0% to -$0.08 in 2023, then soared by 37.5% to -$0.05 in 2024, then fell by 0.0% to -$0.05 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.05, -$0.09, and $0.03 for Q4 2025, Q3 2025, and Q2 2025 respectively.